Pluristyx Partners With Leading Regenerative Medicine and Aerospace Pioneers to Standardize Clinical-Grade Hepatocyte Manufacturing for Space and Earth Applications
Article excerpt
Highlighted: the sentence this signal was extracted from
SEATTLE and WINSTON-SALEM, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Pluristyx, Inc., a leading provider of advanced induced pluripotent stem cell (iPSC) technologies and proprietary, genetically engineered solutions, and Wake Forest Advocate Health today announced a landmark collaborative initiative to develop a standardized, clinical-grade hepatocyte (liver cell) manufacturing workflow. Partnering with the Wake Forest Institute for Regenerative Medicine (WFIRM), Innovian Space, and RegenMed Development Organization (ReMDO), the consortium bridges the frontiers of terrestrial cell therapy and low-Earth orbit (LEO) biotechnology. The partnership represents a critical step toward establishing a commercially scalable manufacturing framework for implantable regenerative medicine products, with applications spanning terrestrial health care, distributed manufacturing and the emerging orbital biomanufacturing economy. Aligned with NASA's In-Space Production Applications (InSPA) program, where the WFIRM team is developing a bridge-to-transplantation approach as a first step toward future whole-organ bioengineering, the joint project establishes a scalable, clinically compliant foundation for advanced tissue engineering. The primary objective is to create a robust supply chain of clinical-grade hepatocytes supporting bridge-to-transplantation therapies, providing temporary...
Keep reading with a free account
The rest of this article, and every signal for Advocate Health, is in your free account.